Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)

NCT02680574 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1725

Enrollment

INDUSTRY

Sponsor class

Conditions

Anemia
Non-Dialysis-Dependent Chronic Kidney Disease

Interventions

DRUG: Vadadustat
DRUG: Darbepoetin alfa

Sponsor

Akebia Therapeutics